P

Inventor

ZHOU LIYING

CN20 patents
⚠️ This page may combine multiple inventors who share the name “ZHOU LIYING”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.

BEIJING TIDE PHARMACEUTICAL CO LTD

19 patents
US10323023B2Jun 18, 2019

Rho-associated protein kinase inhibitor, pharmaceutical composition comprising the same, as well as preparation method and use thereof

BEIJING TIDE PHARMACEUTICAL CO LTD14 citations85
US11919918B2Mar 5, 2024

P2X3 andor P2X2/3 receptor antagonist, pharmaceutical composition comprising same, and use thereof

BEIJING TIDE PHARMACEUTICAL CO LTD6 citations84
US11390609B2Jul 19, 2022

Rho-associated protein kinase inhibitor, pharmaceutical composition comprising same, and preparation method and use thereof

BEIJING TIDE PHARMACEUTICAL CO LTD12 citations84
US10329282B2Jun 25, 2019

Rho-associated protein kinase inhibitor, pharmaceutical composition comprising the same, as well as preparation method and use thereof

BEIJING TIDE PHARMACEUTICAL CO LTD13 citations83
US11414444B2Aug 16, 2022

P2X3 and/or P2X2/3 receptor antagonist, pharmaceutical composition comprising same, and use thereof

BEIJING TIDE PHARMACEUTICAL CO LTD5 citations82
US12180243B2Dec 31, 2024

Receptor inhibitor, pharmaceutical composition comprising same, and use thereof

BEIJING TIDE PHARMACEUTICAL CO LTD2 citations71
US11453690B2Sep 27, 2022

Receptor inhibitor, pharmaceutical composition comprising same, and use thereof

BEIJING TIDE PHARMACEUTICAL CO LTD3 citations71
US12582653B2Mar 24, 2026

Method for treating idiopathic pulmonary fibrosis

BEIJING TIDE PHARMACEUTICAL CO LTD0 citations61
US12509479B2Dec 30, 2025

P2X3 and/or P2X2/3 receptor antagonist, pharmaceutical composition comprising same, and use thereof

BEIJING TIDE PHARMACEUTICAL CO LTD0 citations61
US12485108B2Dec 2, 2025

Method for treating fatty liver disease and/or steatohepatitis

BEIJING TIDE PHARMACEUTICAL CO LTD0 citations61
US12459917B2Nov 4, 2025

Salt of diaminopyrimidine compounds, and solid form thereof, preparation method therefor and use thereof

BEIJING TIDE PHARMACEUTICAL CO LTD0 citations59
US11939578B2Mar 26, 2024

Double-stranded RNA molecule targeting CKIP-1 and use thereof

BEIJING TIDE PHARMACEUTICAL CO LTD0 citations59
US11155819B2Oct 26, 2021

Double-stranded RNA molecule targeting CKIP-1 and use thereof

BEIJING TIDE PHARMACEUTICAL CO LTD0 citations59
US12365665B2Jul 22, 2025

Solid form of diaminopyrimidine compound or hydrate thereof, preparation method therefor, and application thereof

BEIJING TIDE PHARMACEUTICAL CO LTD0 citations58
US12595261B2Apr 7, 2026

P2X3 and/or P2X2/3 receptor antagonist, pharmaceutical composition containing same, and use thereof

BEIJING TIDE PHARMACEUTICAL CO LTD0 citations51
US12398118B2Aug 26, 2025

Rho-associated protein kinase inhibitor, pharmaceutical composition comprising same, and use thereof

BEIJING TIDE PHARMACEUTICAL CO LTD0 citations50
US11905274B2Feb 20, 2024

Receptor inhibitors, pharmaceutical compositions comprising the same and use thereof

BEIJING TIDE PHARMACEUTICAL CO LTD0 citations50
US12544382B2Feb 10, 2026

2, 4, 6-tri-substituted pyrimidine compound as ATR kinase inhibitor

BEIJING TIDE PHARMACEUTICAL CO LTD0 citations48
US11938222B2Mar 26, 2024

Pregabalin sustained release composition and method for preparing the same

BEIJING TIDE PHARMACEUTICAL CO LTD0 citations48

SAMSUNG ELECTRONICS CO LTD

1 patent